The Contribution of Liver Sinusoidal Endothelial Cells to Clearance of Therapeutic Antibody

Abstract

Many chronic inflammatory diseases are treated by administration of “biological” therapies in terms of fully human and humanized monoclonal antibodies or Fc fusion proteins. These tools have widespread efficacy and are favored because they generally exhibit high specificity for target with a low toxicity. However, the design of clinically applicable humanized antibodies is complicated by the need to circumvent normal antibody clearance mechanisms to maintain therapeutic dosing, whilst avoiding development of off target antibody dependent cellular toxicity. Classically, professional phagocytic immune cells are responsible for scavenging and clearance of antibody via interactions with the Fc portion. Immune cells such as macrophages, monocytes, and neutrophils express Fc receptor subsets, such as the FcγR that can then clear immune complexes. Another, the neonatal Fc receptor (FcRn) is key to clearance of IgG in vivo and serum half-life of antibody is explicitly linked to function of this receptor. The liver is a site of significant expression of FcRn and indeed several hepatic cell populations including Kupffer cells and liver sinusoidal endothelial cells (LSEC), play key roles in antibody clearance. This combined with the fact that the liver is a highly perfused organ with a relatively permissive microcirculation means that hepatic binding of antibody has a significant effect on pharmacokinetics of clearance. Liver disease can alter systemic distribution or pharmacokinetics of antibody-based therapies and impact on clinical effectiveness, however, few studies document the changes in key membrane receptors involved in antibody clearance across the spectrum of liver disease. Similarly, the individual contribution of LSEC scavenger receptors to antibody clearance in a healthy or chronically diseased organ is not well characterized. This is an important omission since pharmacokinetic studies of antibody distribution are often based on studies in healthy individuals and thus may not reflect the picture in an aging or chronically diseased population. Therefore, in this review we consider the expression and function of key antibody-binding receptors on LSEC, and the features of therapeutic antibodies which may accentuate clearance by the liver. We then discuss the implications of this for the design and utility of monoclonal antibody-based therapies.

Immunogenicity and safety of an inactivated SARS‐CoV‐2 vaccine in people living with HIV: A cross‐sectional study

“…The liver is vital in human immunity 28 . Interestingly, a recent study also suggested that the liver plays an important role in regulating antibody titers 29 . However, we failed to identify ALT and AST levels as independent factors associated with seropositivity IgG against SARS‐CoV‐2 in PLWH in the present study.…”

Booster shot of inactivated SARS‐CoV‐2 vaccine induces potent immune responses in people living with HIV

“…It appears that the antibody profiles to vaccination prevention in older individuals respond ineffectively and decline easily owing to immunosenescence and comorbidities 38 ; therefore, regular boost shots and shortened vaccine intervals might help. Intriguingly, we found AST and TC as independent factors associated with the positive proportion of NAb to BA.4/5 and IgG anti‐RBD antibodies, suggesting the central function of the liver in regulating antibody production 39,40 …”

Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells

“…Hepatobiliary excretion was associated with considerable liver retention for both RevTMs (Figure 9F). The IgG4-based RevTM showed the highest liver uptake, possibly due to its Fc portion (53,54).…”